ABVC BIOPHARMA, INC. (ABVC) Form 8-K — Aug 27, 2026
ABVC BioPharma completed the partial spin-off of its subsidiary BioKey (Cayman), Inc. on August 21, 2026, distributing 4,500,390 BioKey ordinary shares — approximately 15% of BioKey — to ABVC shareholders as a pro rata dividend of 0.169464 BioKey shares per ABVC share held as of the July 24, 2026 record date. ABVC remains BioKey's controlling shareholder with approximately 85% of its outstanding ordinary shares. BioKey became a separate SEC reporting company when its Form 10 went effective on June 25, 2026, and intends to apply for quotation on the OTC Markets, though no trading market or symbol exists yet.
Key figures
- Record date
- 2026-07-24
- Biokey par value
- $0.0001 per ordinary share
- Distribution ratio
- 0.169464 BioKey ordinary shares per ABVC common share
- Otc listing status
- Application pending; no trading symbol assigned yet
- Shares distributed
- 4500390
- Biokey form10 file no
- 000-56853
- Distribution effective
- 2026-08-21 (11:59 p.m. NYC time)
- Stake retained by abvc
- 85%
- Biokey form10 effective
- 2026-06-25
- Stake distributed to shareholders
- 15%
Price after filing
Close on the filing date to close N calendar days later (from $0.80). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.